Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Smart Imaging Technologies’ Interactive Web Reports for its Simagis Live Digital Pathology servers make it possible for pathologists to complete and sign off digital cases, create professional, media-rich reports from digital slides, and share them instantly with clients, colleagues, or patients.
Wheaton CryoELITE tissue vials feature a wide-mouth opening, 5-mL capacity, and high-integrity closure. The vials offer researchers who work with biological tissue sections ease of use, convenience, and security.
The Allegra X-5 air-cooled benchtop centrifuge from Beckman Coulter Life Sciences is designed specifically for clinical sample preparation. Bundled packages, which include swinging bucket rotors and common adapters, enable fast and convenient setup and are offered for a range of clinical sample prep applications.
Enzo Life Sciences’ high-efficiency BioArray conversion kits for detecting 5-mC and 5-hmC modifications (Express DNA methylation kit, blood and tissue DNA methylation kit, and BioArray 5-hmC methylation kit) allow for resolution of single-nucleotide changes without introducing DNA damage. Features such as capacity for multiple sample inputs, rapid processing time, and high-conversion efficiency rate provide enhanced flexibility without sacrificing performance.
PAML, through a partnership with Verinata Health, is now offering the Verifi prenatal test for all patients within the network desiring noninvasive prenatal testing to detect Down syndrome, Edwards syndrome, Patau syndrome, and sex chromosome abnormalities, the most common genetic abnormalities tested for during pregnancy.
The Clinical and Laboratory Standards Institute has published an updated version of “MM07-A2–Fluorescence In Situ Hybridization Methods for Clinical Laboratories; Approved Guideline–Second Edition.” This document addresses FISH methods for medical genetic determinations, identification of chromosomal abnormalities, and gene amplification.
Waters Corp. has unveiled its Web-based Oasis method development tools, which are designed to help customers reduce their sample preparation method development time as part of Waters’ simple prep campaign.
Denville Scientific’s new line of microscopes includes basic and advanced models designed to provide maximum optical performance on durable and affordable platforms.
The selection includes epifluorescence and stereo-zoom models as well as models with trinocular camera and video mounts. A range of objectives are available, and all microscopes come with a five-year mechanical warranty.
The Liquidator 96 bench-scale manual pipetting solution from Mettler Toledo subsidiary Rainin Instrument provides accuracy without forcing operators to contend with electronic systems or complex computer programming.
Luminex announced it has received FDA and European clearance for a comprehensive genotyping assay, xTAG CYP2C19 kit. This new test provides a personalized approach to determining patient treatment based on certain genetic variants of the P450 2C19 gene.
